Clostridium butyricum inhibits the progression of colorectal cancer and alleviates intestinal inflammation via the myeloid differentiation factor 88 (MyD88)-nuclear factor-kappa B (NF-κB) signaling pathway

BACKGROUND: Clostridium butyricum (C. butyricum, CB) is a probiotic to modulate the intestinal disorders and CB supplement has been found to have a great impact on inflammation and cancer treatment. However, the effects and mechanisms of CB on colorectal cancer (CRC) are not clear. We performed this...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mingyao, Yuan, Wei, Yang, Bing, Pei, Wei, Ma, Jie, Feng, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096358/
https://www.ncbi.nlm.nih.gov/pubmed/35571406
http://dx.doi.org/10.21037/atm-22-1670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096358/
https://www.ncbi.nlm.nih.gov/pubmed/35571406
http://dx.doi.org/10.21037/atm-22-1670

Ejemplares similares